# Circulating Tumour DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation

> **NCT04089631** · PHASE3 · RECRUITING · sponsor: **Technische Universität Dresden** · enrollment: 4812 (estimated)

## Conditions studied

- Colon Cancer Stage II

## Interventions

- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT04089631
- **Lead sponsor:** Technische Universität Dresden
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-06-26
- **Primary completion:** 2023-06
- **Final completion:** 2026-06
- **Target enrollment:** 4812 (ESTIMATED)
- **Last updated:** 2020-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04089631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04089631, "Circulating Tumour DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04089631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*